Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

May 28, 2002; 58 (10) Articles

Hippocampal volume as an index of Alzheimer neuropathology

Findings from the Nun Study

K. M. Gosche, J. A. Mortimer, C. D. Smith, W. R. Markesbery, D. A. Snowdon
First published May 28, 2002, DOI: https://doi.org/10.1212/WNL.58.10.1476
K. M. Gosche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. A. Mortimer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. D. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. R. Markesbery
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. A. Snowdon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Hippocampal volume as an index of Alzheimer neuropathology
Findings from the Nun Study
K. M. Gosche, J. A. Mortimer, C. D. Smith, W. R. Markesbery, D. A. Snowdon
Neurology May 2002, 58 (10) 1476-1482; DOI: 10.1212/WNL.58.10.1476

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1396

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective: To determine whether hippocampal volume is a sensitive and specific indicator of Alzheimer neuropathology, regardless of the presence or absence of cognitive and memory impairment.

Methods: Postmortem MRI scans were obtained for the first 56 participants of the Nun Study who were scanned. The area under receiver operating characteristic curves, sensitivity, specificity, and positive and negative predictive values were used to assess the diagnostic accuracy of hippocampal volume in predicting fulfillment of Alzheimer neuropathologic criteria and differences in Braak staging.

Results: Hippocampal volume predicted fulfillment of neuropathologic criteria for AD for all 56 participants (p < 0.001): 24 sisters who were demented (p = 0.036); 32 sisters who remained nondemented (p < 0.001), 8 sisters who remained nondemented but had memory impairment (p < 0.001), and 24 sisters who were intact with regard to memory and cognition at the final examination prior to death (p = 0.003). In individuals who remained nondemented, hippocampal volume was a better indicator of AD neuropathology than a delayed memory measure. Among nondemented sisters, Braak stages III and VI were distinguishable from Braak stages II or lower (p = 0.001). Among cognitively intact individuals, those in Braak stage II could be distinguished from those in stage I or less (p = 0.025).

Conclusion: Volumetric measures of the hippocampus may be useful in identifying nondemented individuals who satisfy neuropathologic criteria for AD as well as pathologic stages of AD that may be present decades before initial clinical expression.

Pathologic1-4⇓⇓⇓ and neuroimaging5-9⇓⇓⇓⇓ studies have shown that the hippocampal formation is particularly vulnerable to neuronal loss and atrophic changes during the course of AD. Although a sensitive marker of AD, hippocampal atrophy is not specific for this illness, as this condition has been described in a number of other neurologic disorders,10-12⇓⇓ as well as in nondemented elderly and individuals with mild cognitive impairment (MCI).7,9,13,14⇓⇓⇓ Hippocampal atrophy also has been shown to be predictive of decline from MCI to dementia.15-18⇓⇓⇓

Previous studies examining the association of hippocampal atrophy with AD have lacked autopsy confirmation. Therefore, it remains uncertain whether hippocampal atrophy is associated only with the clinical expression of AD or whether it also is a predictor of underlying AD neuropathology in individuals without clinical signs of dementia. The longitudinal design of the Nun Study, combining premorbid evaluation, postmortem MRI, and quantitative neuropathologic indexes of AD, provides an opportunity to examine the value of hippocampal atrophy in predicting the presence of AD neuropathology in individuals who remain nondemented.

In the current study, we employed volumetric measures of the hippocampus derived from postmortem MRI scans to examine the association of hippocampal volume with the presence and severity of AD neuropathology. We hypothesized that hippocampal volume would be a sensitive and specific indicator of Alzheimer neuropathology, regardless of the presence or absence of cognitive and memory impairment.

Methods.

Study population.

Participants in the Nun Study are members of the School Sisters of Notre Dame congregation and live in communities in the midwestern, eastern, and southern United States. The Nun Study, a longitudinal study of aging and AD, is described in more detail elsewhere.19-21⇓⇓ Cognitive and physical functions were assessed annually, and all participants agreed to brain donation at death. By early 1998, 256 sisters had died and received a neuropathologic evaluation. Postmortem MRI scans were initiated beginning in 1996, and the current sample is based on the first 56 brains that were scanned.

Assessment of dementia.

Cognitive function was evaluated annually using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological battery, which assesses memory, concentration, language, visuospatial ability, and orientation to time and place.22 Assessments of social and daily function were made using performance-based testing.23,24⇓

Individuals considered to be demented in our study had each of the following conditions: 1) impairment in memory, indicated by a score of <4 on the Delayed Word Recall Test; 2) impairment in at least one other area of cognition, indicated by scores of <11 on the Verbal Fluency Test, <13 on the Boston Naming Test, or <8 on the Constructional Praxis Test; 3) impairment in basic or instrumental activities of daily living (defined by inability to use a telephone, handle money, or dress oneself); and 4) evidence of decline in ability from a previous level attributable to cognitive impairment. The cutoffs used to identify impairments in cognition were based on scores that were less than the fifth percentile for the normative data described by the CERAD group.25

Neuropathologic evaluation.

Gross and microscopic evaluations of the participants’ brains were performed by a neuropathologist who was blinded to the participants’ cognitive test scores. For histopathologic evaluation, multiple sections of neocortex, hippocampus, entorhinal cortex, amygdala, basal ganglia, brainstem, and cerebellum were stained with hematoxylin and eosin and the modified Bielschowsky stain. Senile plaques (both diffuse and neuritic types) and neurofibrillary tangles were counted in Bielschowsky-stained sections of the five most severely involved microscopic fields of the middle frontal gyrus (Brodmann area 9), inferior parietal lobule (areas 39/40), middle temporal gyrus (area 21), and CA1 region of the hippocampus. In addition, brains were staged for the severity of neurofibrillary pathology using Gallyas and Bielschowsky stains.2

To meet the study’s neuropathologic criteria for AD, participants were required to have 1) ≥16 senile plaques/mm2 microscopic field in the frontal, temporal, or parietal lobe of the neocortex (sufficient to meet the Khachaturian criteria26); 2) neuritic plaques in the frontal, temporal, or parietal lobe; and 3) neurofibrillary tangles in the frontal, temporal, or parietal lobe.

Postmortem brain preparation and MRI acquisition.

The brain was removed from formalin, inspected for cuts or gross lesions, and immersed for 15 minutes in cold water. It was then placed in a watertight plastic cylinder containing dilute formalin and rotated to remove bubbles and trapped air from the ventricles. Paper packing was used to prevent movement of the brain within the container during imaging. This inner container was anchored in an outer water-filled loader aligned with fiducial markers. The loader was carefully centered in the head coil using the same fiducials.

MRI was performed on a 1.5 T scanner. Three-dimensional T1-weighted coronal images of the entire brain were acquired using a magnetization prepared rapid gradient echo [MP RAGE] sequence (repetition time [TR] = 11 milliseconds, echo time [TE] = 4 milliseconds, 180 × 2562 matrix, flip angle = 8°, true resolution = 1 × 1 × 2 mm). Additional axial slice series were acquired in a plane parallel to the anterior commissure–posterior commissure line (T1-weighted: TR = 400 milliseconds, TE = 18 milliseconds, true resolution = 0.5 × 0.5 × 3 mm; T2-weighted double echo: TR = 2,500 milliseconds, TE = 20 and 80 milliseconds, true resolution = 1 × 1 × 3 mm).

To reduce the influence of differences in fixation time, we attempted to keep this delay uniform in duration across brains. On average, MRI scanning was performed 6 weeks following death.

Imaging analyses.

Hippocampal volumes were calculated by an automated program called the Knowledge-Guided MRI Analyses Program (KGMAP). A more complete description of this program and its validation against manual tracing methods are given elsewhere.27,28⇓ KGMAP’s logic combines knowledge rules based on intensities with the spatial relationship of anatomic structures. The combination of these rules results in the localization and identification of regional structures of interest throughout the brain. Once identified, the volume of each region is calculated and regional analyses are performed.

Briefly, KGMAP analyses begin with the identification of the lateral ventricles, caudate nuclei, lenticular nuclei, and thalamus in the first image. The locations of these structures, once identified, are used to identify their possible presence in subsequent slices. KGMAP begins searching for the hippocampus on the first image. However, the hippocampus typically does not begin to appear until the image where the temporal horn and body of the lateral ventricle separate in the axial plane. This generally occurs within two axial images below the first image analyzed by KGMAP. As the analysis of KGMAP works downward from the first image into the temporal lobe of the brain, the gray matter comprising the hippocampus is initially identified as that tissue in the space separating the temporal horn and body of the lateral ventricle. In the axial plane, its superior border lies inferior to the remaining body of the lateral ventricle, while its lateral and inferior borders lie medial and superior to the temporal horn of the lateral ventricle. In the case of minimal atrophy, the CSF in this region can be convoluted by partial volume effects in the surrounding tissue. If a strong indication of CSF is not present, the lateral and inferior borders are identified by pixels indicating a strong presence of white matter. If these procedures do not completely isolate these borders, an algorithm-generated interpretative line, aided by pixels that were found, is used to close the bordering line. The use of hippocampal pixel locations from previous slices aids greatly in the total identification of this structure. Volumetric measures are calculated through a summation procedure that includes all images in which the hippocampus is identified.

Data analysis.

Because AD neuropathology was assessed using sections from the left hemisphere and our primary interest was the association of hippocampal atrophy and neuropathologic markers, we used left hippocampal volume to correlate with neuropathologic outcomes. When similar analyses were performed using right hippocampal volume and AD neuropathology from the left hemisphere, the findings were not significantly different. The sensitivity and specificity of left hippocampal volume as a predictor of Alzheimer neuropathology were obtained for every observed value and represented as receiver operating characteristic (ROC) curves.29 ROC curves are generated by calculating the sensitivity and specificity of every observed predictor value and plotting 1-specificity against sensitivity. The area under the ROC curve was used to assess the diagnostic accuracy of hippocampal volume in predicting fulfillment of AD neuropathologic criteria as well as differences in Braak staging. To assess whether age and education affected the diagnostic accuracy of hippocampal volume, all ROC curves were rerun using hippocampal volume adjusted for age and education. All analyses utilized SPSS 10.1 for Windows (SPSS, Chicago, IL). This program provides 95% CI for the area under the ROC curve and generates estimates of statistical significance of the departure from neutrality (area = 0.5). Finally, we compared different predictors of the same outcome (satisfaction of neuropathologic criteria for AD) using standard procedures.30 This approach reduces the standard error of between-area differences by taking into account correlations between two different variables measured on the same sample, resulting in an increased power of the test.

Although high sensitivity is desirable, the practical application of this technique to detect very early, asymptomatic cases of AD could lead to false identification of individuals as AD cases, with consequent ethical problems. Therefore, in specifying optimum cut points for separating individuals with specific levels of neuropathologic lesions, we adopted a minimum specificity of 80%. Optimum cut points were selected as those contributing to the highest sum of specificity and sensitivity in which the specificity was ≥80%.

Differences in means for age at death, interval between last exam and death, Mini-Mental State Examination (MMSE) score at the final exam before death, years of education, Braak stage, and left hippocampal volume were evaluated in four groups defined by satisfaction of neuropathologic criteria for AD and presence/absence of dementia using a one-way analysis of variance. Post hoc comparisons utilized Bonferroni adjustment for multiple comparisons.

Results.

Summary of cases.

The sample of 56 sisters analyzed in this study included 33 who fulfilled neuropathologic criteria for AD and 23 who did not. The relatively high percentage of sisters fulfilling neuropathologic criteria is likely the result of the high mean age at death31 and the fact that mortality is higher among individuals with this disease,32 which would increase their representation in the group that dies first. Table 1 shows characteristics of the four groups defined by neuropathology and dementia. Demented sisters had fewer years of education than nondemented sisters (p < 0.05), and Braak stage was higher in those meeting AD neuropathologic criteria (p < 0.001). The volume of the left hippocampus was smaller among demented sisters meeting AD neuropathologic criteria than in the other three groups (p < 0.01) and larger (p < 0.01) among nondemented sisters who did not meet neuropathologic criteria than in both groups who met these criteria. Finally, both groups of demented sisters had lower MMSE scores at the final evaluation prior to death in comparison with both groups of nondemented sisters (p < 0.01). Mean MMSE scores obtained by the two demented groups were not significantly different from each other, nor were mean scores obtained by the two nondemented groups significantly different from each other.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of 56 participants defined by neuropathology and dementia status

Predictive value of hippocampal volume in detecting neuropathologic AD.

Table 2 summarizes the findings of ROC analyses for the entire sample as well as several subgroups. The predictor is the inverse of left hippocampal volume (greater volumes correspond to lower values) and the predicted outcome is fulfillment of neuropathologic criteria for AD. For the entire sample, the area under the ROC curve is 0.91 (95% CI: 0.83 to 1.00; p < 0.001). Sensitivity at the optimum cut point was 0.82 and specificity 0.87. The positive predictive value of a hippocampal volume less than the cut point was 0.90 and negative predictive value 0.77. To determine the predictive value of hippocampal volume in individuals who did not exhibit dementia during life, we conducted similar ROC analyses for the 32 sisters who remained nondemented as well as two subgroups: 8 sisters who remained nondemented but were judged to have a significant memory impairment in the absence of other cognitive impairments (“memory impaired”) and 24 sisters who were intact with regard to memory and cognition at the final examination prior to death (“cognitively normal”). Memory impairment was determined by a score of <4 of a possible 10 on the CERAD Delayed Word Recall Test, whereas cut points for other cognitive impairments were the same as those described above in Assessment of dementia. Although lacking evidence of memory complaint, the nondemented group with a significant memory impairment would be similar to the group identified with clinical criteria for MCI.33 Finally, we conducted an ROC analysis for the 24 demented sisters.

View this table:
  • View inline
  • View popup
Table 2.

Summary of receiver operating characteristic analyses predicting fulfillment of neuropathologic criteria for AD

Areas under the curve and their 95% CI, sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values at the optimum cut points are shown in table 2 for these groups. In every group, hippocampal volume significantly predicted group membership. Areas under the respective ROC curves were similar to each other. All ROC analyses were rerun, adjusting hippocampal volume for age and education. In almost all cases, these adjustments had no effect on the ROC curve. The only difference seen was a slight, nonsignificant decrease in area under the curve from 0.923 to 0.917 for the analysis of the 32 nondemented sisters.

Hippocampal volume compared with delayed memory measure in nondemented sisters.

To determine whether hippocampal volume was a better indicator of AD neuropathology than a delayed memory measure among individuals who remained nondemented, we compared ROC curves for the inverse of left hippocampal volume with the number of words (up to 10) from the CERAD Word List Test not recalled after a delay (figure 1). Areas under the curves were 0.92 (95% CI: 0.83 to 1.02) and 0.78 (95% CI: 0.60 to 0.96) for hippocampal volume and delayed memory. The difference between areas was 0.14 (95% CI: −0.03 to 0.32; p = 0.11). Although the difference between areas was not significant, at the optimum cut points, the positive and negative predictive values for hippocampal volume (0.82 and 1.00) were larger than those for delayed memory (0.75 and 0.75).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 1. Receiver operating characteristic curves comparing prediction of fulfillment of AD neuropathologic criteria from the inverse of left hippocampal volume (solid line) and number of words not recalled in the final administration of the Consortium to Establish a Registry for Alzheimer’s Disease Delayed Word Recall Test before death (dashed line).

Hippocampal volume prediction of Braak staging in nondemented sisters.

To assess whether hippocampal volume was a sensitive and specific indicator of the Alzheimer degenerative process prior to spread of neurofibrillary tangles to the cortex, we investigated the value of hippocampal volume in predicting Braak stage in our nondemented subsample. Of the 32 nondemented sisters, 20 were rated Braak stage II or lower, whereas 12 were reported as having Braak stage III or VI. Figure 2A shows the ROC curve for this analysis, where the outcome is Braak stage III to VI vs Braak stage II or less. The area under this curve is 0.84 (95% CI: 0.70 to 0.99; p = 0.001). With use of the same definition for an optimum cut point, sensitivity was 0.83 and specificity 0.80. Positive and negative predictive values were 0.71 and 0.89.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure 2. Receiver operating characteristic curves showing prediction of Braak stages III and IV from Braak stages II and lower in 32 nondemented sisters (A) and prediction of Braak stage II from Braak stages I or lower among 18 sisters with Braak stages II or less who were cognitively normal (B).

We repeated these analyses restricting our subject group to the 18 individuals who maintained normal cognition and received a Braak stage of II or less. Figure 2B shows the ROC curve comparing the 12 individuals in stage II with the 6 in stage I or less. In this analysis, the area under the curve was 0.83 (95% CI: 0.63 to 1.04; p = 0.025), and sensitivity, specificity, positive predictive value, and negative predictive value at the optimum cut point were 0.58, 0.92, 0.88, and 0.50.

Discussion.

The findings suggest that hippocampal volumes may be valuable not only in distinguishing individuals with AD from the nondemented elderly but also in identifying individuals with AD neuropathology who have yet to demonstrate dementia or even memory impairment. The finding that hippocampal volume predicts differences between Braak stages I or less and Braak stage II suggests that volumetric measures of the hippocampus could be useful in detecting some of the earliest pathologic stages of this illness that may be present several decades before clinical symptoms become apparent.31 Although the findings demonstrate an important predictive role for hippocampal volume, application of the technique to MR scans from living people requires additional studies to confirm its validity in this group and to adjust critical cut scores in volume to best separate individuals at different stages of the disease process.

Our study follows many MRI studies that have reported hippocampal volume differences between patients with clinically diagnosed AD and normal control subjects,5-9,33-35⇓⇓⇓⇓⇓⇓⇓ between patients with MCI and normal control subjects,7,9,34,35⇓⇓⇓ and between patients with MCI who progress to dementia and those who do not.15,17,36⇓⇓ These studies generally have shown that although hippocampal volume is a strong predictor of clinical AD and MCI, there is considerable overlap, with some cognitively normal control subjects also showing atrophy. The demonstration that many apparently cognitive normal elderly may harbor Alzheimer lesions sufficient to meet neuropathologic criteria for this disease20,37-39⇓⇓⇓ raises the question of whether some of the normal control subjects in these studies may have had the illness without showing signs. The current study shows that >40% of those meeting study neuropathologic criteria were not demented at their last clinical exam an average of 1.04 years prior to death.

A recent review of the neuropsychology of preclinical AD and MCI40 concluded that cognitive decline on tasks that involve episodic learning and recall is consistently reported as being able to discriminate between individuals with preclinical AD and normal elderly control subjects. Furthermore, the memory deficits in preclinical AD are associated with damage to the hippocampus and surrounding structures of the medial temporal lobe.40 Of these measures, our data suggest that hippocampal volume is a somewhat better indicator of AD neuropathology than a delayed recall measure in individuals who are not yet demented.

The neuropathologic process associated with AD is thought to begin years before the initial clinical signs.41,42⇓ Recently, it has been demonstrated that the neurofibrillary changes characteristic of preclinical stages of AD (stages I to II) can be observed in a substantial proportion of individuals as young as 25 years.31 In a follow-up commentary of this study, the age distributions of cases in the various Braak stages were recalculated under the assumption that every case at a later stage would have also been classified as positive at all earlier stages.43 The resulting curve showed that progression to stages III to IV occurs over the course of several decades. These studies support the concept of a long preclinical stage of this illness.42,44,45⇓⇓ Our data suggest that hippocampal volume may be predictive of individuals in early preclinical stages of the disease. Furthermore, the hippocampal volume measure has a high positive predictive value (0.88) in identifying those individuals in stage II compared with those in stage I or lower. Hippocampal atrophy therefore may provide an additional index useful in identifying individuals at high risk for AD several decades before clinical expression.

Among nondemented subjects, the positive predictive value for low hippocampal volume was 0.82, whereas the negative predictive value was 1.00 at the optimum cut point. The presence of false positives (leading to a positive predictive value of <1) is consistent with previous findings10-12⇓⇓ showing that hippocampal atrophy is not specific for AD. Addition of volumes from other brain regions affected early in the course of AD may be needed to improve the predictive accuracy of MRI-based algorithms.

The percentage of nondemented cases that met criteria for pathologic diagnosis of AD was high (44%). However, it is consistent with other studies37,39⇓ that have reported substantial percentages (43 to 67%) of individuals who remained nondemented during life and fulfilled neuropathologic criteria for AD at autopsy. The high age at death of the current sample combined with the strong association between age and the prevalence of Alzheimer lesions likely explains the presence of such a large number of individuals who fulfilled neuropathologic criteria for the disease without clinical expression.

The fact that the mean MMSE score at the last examination prior to death was relatively low (25.6) in those sisters judged to be cognitively normal is likely attributable to the advanced age of the sisters and the fact that many of them were institutionalized in a nursing facility at the time of evaluation. Previous research has demonstrated that a substantial percentage of older nursing home residents perform relatively poorly on the MMSE but are not demented using Diagnostic and Statistical Manual of Mental Disorders (3rd revised edition) criteria.46

An important limitation of our study was the use of postmortem MRI. Although postmortem MRI has the advantage of permitting correlations between hippocampal volume and neuropathology at the time of death, additional research is needed to demonstrate that hippocampal volumes determined pre and post mortem have similar associations with AD neuropathology.

A second limitation is that the time interval between the last clinical evaluation and death, an average of 1.04 years in our study, may contribute to some misclassification in dementia status at the time of death. However, given the relatively low rate of conversion from cognitive normality to dementia in a single year, it is unlikely that the findings would be substantially different had dementia been assessed closer to the time of death.

Finally, the hippocampal volumes used in the current calculations could not be adjusted for total intracranial volume because the brains had been removed from the cranium prior to scanning. However, when ROC curves were run with hippocampal volume adjusted for total brain volume at autopsy, there were no significant differences in the findings. Furthermore, the fact that all of the participants were female reduced the variability in intracranial volume that would have occurred had the participants included both males and females. In the latter case, absolute hippocampal volumes may not have been as effective in distinguishing individuals with AD neuropathology from those without. Clearly, if the algorithm is used in living people, adjustment needs to be made for total intracranial volume and cutoff values established that best separate those with presumed AD from those without this disease.

Acknowledgments

Supported by grants R01AG09862 (D.A.S.), K04AG00553 (D.A.S.), and 5P50AG05144 (W.R.M.) from the National Institute on Aging, and grants from the Kleberg Foundation and the Abercrombie Foundation.

Acknowledgment

The authors thank the members, leaders, and health care providers of the School Sisters of Notre Dame religious congregation for their spirited support, especially Sisters Marlene Manney and Gabriel Mary Spaeth, as well as Lydia Greiner, Huaichen Liu, Ela Patel, Jeanne Ray, and Cecil Runyons.

  • Received January 25, 2001.
  • Accepted February 5, 2002.

References

  1. ↵
    Bobinski M, Wegiel J, Wisniewski HM, et al. Neurofibrillary pathology—correlation with hippocampal formation atrophy in Alzheimer disease. Neurobiol Aging . 1996; 17: 909–919.
    OpenUrlPubMed
  2. ↵
    Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol . 1991; 82: 239–259.
    OpenUrlCrossRefPubMed
  3. ↵
    Bobinski M, de Leon MJ, Tarnawski M, et al. Neuronal and volume loss in CA1 of the hippocampal formation uniquely predicts duration and severity of Alzheimer disease. Brain Res . 1998; 805: 267–269.
    OpenUrlCrossRefPubMed
  4. ↵
    Bobinski M, Wegiel J, Wisniewski HM, et al. Atrophy of hippocampal formation subdivisions correlates with stage and duration of Alzheimer disease. Dementia . 1995; 6: 205–210.
  5. ↵
    Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology . 1991; 41: 51–54.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology . 1997; 49: 786–794.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    De Leon MJ, George AE, Golomb J, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer’s disease. Neurobiol Aging . 1997; 18: 1–11.
    OpenUrlCrossRefPubMed
  8. ↵
    Detoledo-Morrell L, Sullivan MP, Morrell F, Wilson RS, Bennett DA, Spencer S. Alzheimer’s disease: in vivo detection of differential vulnerability of brain regions. Neurobiol Aging . 1997; 18: 463–468.
    OpenUrlCrossRefPubMed
  9. ↵
    Convit A, De Leon MJ, Tarshish C, et al. Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging . 1997; 18: 131–138.
    OpenUrlCrossRefPubMed
  10. ↵
    Webb J, Guimond A, Eldridge P, et al. Automatic detection of hippocampal atrophy on magnetic resonance images. Magn Res Imag . 1999; 17: 1149–1161.
    OpenUrl
  11. ↵
    Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry . 2000; 157: 16–25.
    OpenUrlPubMed
  12. ↵
    Agartz I, Momenan R, Rawlings RR, Kerich MJ, Hommer DW. Hippocampal volume in patients with alcohol dependence. Arch Gen Psychiatry . 1999; 56: 356–363.
    OpenUrlCrossRefPubMed
  13. ↵
    Golomb J, de Leon MJ, Kluger A, George AE, Tarshish C, Ferris SH. Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch Neurol . 1993; 50: 967–973.
    OpenUrlCrossRefPubMed
  14. ↵
    Golomb J, Kluger A, de Leon MJ, et al. Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Learning Memory . 1994; 1: 45–54.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology . 1999; 52: 1397–1403.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Convit A, de Asis J, de Leon MJ, Tarshish CY, De Santi S, Rusinek H. Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer’s disease. Neurobiol Aging . 2000; 21: 19–26.
    OpenUrlPubMed
  17. ↵
    Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer’s disease. Ann Neurol . 2000; 47: 430–439.
    OpenUrlCrossRefPubMed
  18. ↵
    de Leon MJ, Golomb J, George AE, et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR . 1993; 14: 897–906.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR. Linguistic ability in early life and cognitive function and Alzheimer’s disease in late life. Findings from the Nun Study. JAMA . 1996; 275: 528–532.
    OpenUrlCrossRefPubMed
  20. ↵
    Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA . 1997; 277: 813–817.
    OpenUrlCrossRefPubMed
  21. ↵
    Snowdon DA. Aging and Alzheimer’s disease: lessons from the Nun Study. Gerontologist . 1997; 37: 150–156.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology . 1989; 39: 1159–1165.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Potvin AR, Tourtellotte WW, Dailey JS, et al. Simulated activities of daily living examination. Arch Phys Med Rehabil . 1972; 53: 476–486
    OpenUrlPubMed
  24. ↵
    Kuriansky JB, Gurland BJ, Fleiss JL. The assessment of self-care capacity in geriatric psychiatric patients by objective and subjective methods. J Clin Psychol . 1976; 32: 95–102.
    OpenUrlPubMed
  25. ↵
    Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology . 1994; 44: 609–614.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol . 1985; 42: 1097–1105.
    OpenUrlCrossRefPubMed
  27. ↵
    Gosche KM, Velthuizen RP, Murtagh RF, et al. Automated quantification of brain magnetic resonance image hyperintensities using hybrid clustering and knowledge-based methods. Int J Imag Sci Technol . 1999; 10: 287–293.
  28. ↵
    Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. An automated technique for measuring hippocampal volumes from MR imaging studies. AJNR . 2001; 22: 1686–1689.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. Br Med J . 1994; 309: 188.
    OpenUrlFREE Full Text
  30. ↵
    Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology . 1983; 148: 839–843.
    OpenUrlPubMed
  31. ↵
    Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging . 1997; 18: 351–357.
    OpenUrlCrossRefPubMed
  32. ↵
    Kokmen E, Chandra V, Schoenberg BS. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods, 1960–1974. Neurology . 1988; 38: 975–980.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol . 1999; 56: 303–308.
    OpenUrlCrossRefPubMed
  34. ↵
    Jack CR Jr, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol . 1998; 43: 303–310.
    OpenUrlCrossRefPubMed
  35. ↵
    Laakso MP, Soininen H, Partanen K, et al. MRI of the hippocampus in Alzheimer’s disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. Neurobiol Aging . 1998; 19: 23–31.
    OpenUrlCrossRefPubMed
  36. ↵
    Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Arch Neurol . 1993; 50: 949–954.
    OpenUrlCrossRefPubMed
  37. ↵
    Morris JC, McKeel DW Jr, Fulling K, Torack RM, Berg L. Validation of clinical diagnostic criteria for Alzheimer’s disease. Ann Neurol . 1988; 24: 17–22.
    OpenUrlCrossRefPubMed
  38. ↵
    Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol . 1988; 23: 138–144.
    OpenUrlCrossRefPubMed
  39. ↵
    Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer’s disease. Neurology . 1988; 38: 1682–1687.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Collie A, Maruff P. The neuropsychology of preclinical Alzheimer’s disease and mild cognitive impairment. Neurosci Biobehav Rev . 2000; 24: 365–374.
    OpenUrlCrossRefPubMed
  41. ↵
    Racagni G, Brunello N, Langer SZ. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. New York: Karger, 1994.
  42. ↵
    Grady CL, Haxby JV, Horwitz B, et al. Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol . 1988; 10: 576–596.
    OpenUrlPubMed
  43. ↵
    Silverman W, Wisniewski HM, Bobinski M, Wegiel J. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging . 1997; 18: 377–379.
    OpenUrlCrossRefPubMed
  44. ↵
    Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol . 1992; 31: 242–249.
    OpenUrlCrossRefPubMed
  45. ↵
    Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology . 1993; 43: 2457–2465.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    Nadler JD, Relkin NR, Cohen MS, Hodder RA, Reingold J, Plum F. Mental status testing in the elderly nursing home population. J Geriatr Psychiatry Neurol . 1995; 8: 177–183.

Letters: Rapid online correspondence

  • Autopsy-confirmation of hippocampal atrophy in AD
    • A. David Smith, Professor of Pharmacology, University of Oxforddavid.smith@pharm.ox.ac.uk
    Submitted June 27, 2002
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Methods.
    • Results.
    • Discussion.
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Alzheimer's disease
  • MRI
  • Volumetric MRI

Alert Me

  • Alert me when eletters are published
Neurology: 100 (13)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise